 | Up a level |
López-Fernández, Teresa; Farmakis, Dimitrios; Ameri, Pietro; Asteggiano, Riccardo; de Azambuja, Evandro; Aznar, Marianne; Barac, Ana; Bayes-Genis, Antoni; Bax, Jeroen J; Bergler-Klein, Jutta; Boriani, Giuseppe; Celutkiene, Jelena; Coats, Andrew; Cohen-Solal, Alain; Córdoba, Raúl; Cosyns, Bernard; Filippatos, Gerasimos; Fox, Kevin; Gulati, Geeta; Inciardi, Riccardo M; ... (2024). European Society of Cardiology Core Curriculum for Cardio-Oncology. European journal of heart failure, 26(4), pp. 754-771. Wiley 10.1002/ejhf.3102
Lyon, Alexander R; López-Fernández, Teresa; Couch, Liam S; Asteggiano, Riccardo; Aznar, Marianne C; Bergler-Klein, Jutta; Boriani, Giuseppe; Cardinale, Daniela; Cordoba, Raul; Cosyns, Bernard; Cutter, David J; de Azambuja, Evandro; de Boer, Rudolf A; Dent, Susan F; Farmakis, Dimitrios; Gevaert, Sofie A; Gorog, Diana A; Herrmann, Joerg; Lenihan, Daniel; Moslehi, Javid; ... (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, 43(41), pp. 4229-4361. Oxford University Press 10.1093/eurheartj/ehac244
Tutt, Andrew N J; Garber, Judy E; Kaufman, Bella; Viale, Giuseppe; Fumagalli, Debora; Rastogi, Priya; Gelber, Richard D; de Azambuja, Evandro; Fielding, Anitra; Balmaña, Judith; Domchek, Susan M; Gelmon, Karen A; Hollingsworth, Simon J; Korde, Larissa A; Linderholm, Barbro; Bandos, Hanna; Senkus, Elżbieta; Suga, Jennifer M; Shao, Zhimin; Pippas, Andrew W; ... (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England journal of medicine, 384(25), pp. 2394-2405. Massachusetts Medical Society 10.1056/NEJMoa2105215
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
Procter, Marion; Suter, Thomas M; de Azambuja, Evandro; Dafni, Urania; van Dooren, Veerle; Muehlbauer, Susanne; Climent, Miguel Angel; Rechberger, Ernst; Liu, Walter Tsang-Wu; Toi, Mazakasu; Coombes, R Charles; Dodwell, David; Pagani, Olivia; Madrid, Jorge; Hall, Marcia; Chen, Shin-Cheh; Focan, Christian; Muschol, Michael; van Veldhuisen, Dirk J and Piccart-Gebhart, Martine J (2010). Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. Journal of clinical oncology, 28(21), pp. 3422-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2009.26.0463
de Azambuja, Evandro; Bedard, Philippe L; Suter, Thomas; Piccart-Gebhart, Martine (2009). Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Targeted oncology, 4(2), pp. 77-88. Paris: Springer 10.1007/s11523-009-0112-2
